SkylineDx's Merlin CP-GEP Granted FDA Breakthrough Device Designation, Building on Exclusive NCCN Recognition in Melanoma Care

Merlin CP-GEP, a melanoma gene expression profiling test, received FDA Breakthrough Device designation and is included in NCCN guidelines for T1b and T2a cutaneous melanoma patients. The FDA designation highlights the test’s potential to address an unmet clinical need in early-stage melanoma decision-making. Overall, the regulatory and guideline validation is a modest positive catalyst for market adoption.

Analysis

Merlin CP-GEP, a melanoma gene expression profiling test, received FDA Breakthrough Device designation and is included in NCCN guidelines for T1b and T2a cutaneous melanoma patients. The FDA designation highlights the test’s potential to address an unmet clinical need in early-stage melanoma decision-making. Overall, the regulatory and guideline validation is a modest positive catalyst for market adoption.